Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Accured Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Change in Accured Expenses for 4 consecutive years, with $34.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 70.74% to $34.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.1 million, a 2.38% decrease, with the full-year FY2025 number at $34.1 million, down 2.38% from a year prior.
  • Change in Accured Expenses was $34.1 million for Q4 2025 at Phathom Pharmaceuticals, up from -$5.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $34.1 million in Q4 2025 to a low of -$7.0 million in Q1 2025.
  • A 4-year average of $4.4 million and a median of $139500.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 48946.67% in 2024, then crashed 4423.6% in 2025.
  • Phathom Pharmaceuticals' Change in Accured Expenses stood at -$4.4 million in 2022, then skyrocketed by 104.31% to $189000.0 in 2023, then skyrocketed by 10451.85% to $19.9 million in 2024, then soared by 70.74% to $34.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Change in Accured Expenses are $34.1 million (Q4 2025), -$5.4 million (Q3 2025), and $12.4 million (Q2 2025).